We are live on ! Find out more
GANX icon

Gain Therapeutics
GANX

19 hedge funds and large institutions have $5.71M invested in Gain Therapeutics in 2021 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

36% more funds holding

Funds holding: 14 → 19 (+5)

1.37% more ownership

Funds ownership: 7.51% → 8.89% (+1.4%)

14% less capital invested

Capital invested by funds: $6.65M → $5.71M (-$939K)

Holders
19
Holders Change
+5
Holders Change %
+35.71%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
4
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TI
Telemetry Investments
New York
+$379K
2
CM
CM Management
Florida
+$177K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$138K
4
Two Sigma Investments
Two Sigma Investments
New York
+$134K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$134K

Top Sellers

Rank Fund Capital Flow
1
IAP
Indie Asset Partners
Indiana
-$221K
2
BlackRock
BlackRock
New York
-$2.19K
3
SPIA
Steward Partners Investment Advisory
New York
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
GC
1
Greenlight Capital
New York
$2.97M – – –
TI
2
Telemetry Investments
New York
$807K +$379K +54,900 +57%
CM
3
CM Management
Florida
$489K +$177K +25,673 +40%
PCM
4
Prelude Capital Management
New York
$315K – – –
BCM
5
Bridgeway Capital Management
Texas
$267K – – –
V
6
Veritable
Delaware
$136K – – –
Geode Capital Management
7
Geode Capital Management
Massachusetts
$107K +$138K +20,056 New
Two Sigma Investments
8
Two Sigma Investments
New York
$106K +$134K +19,467 New
Susquehanna International Group
9
Susquehanna International Group
Pennsylvania
$103K +$134K +19,357 New
Millennium Management
10
Millennium Management
New York
$84K +$109K +15,754 New
Citadel Advisors
11
Citadel Advisors
Florida
$70K +$89.9K +13,029 New
BlackRock
12
BlackRock
New York
$60K -$2.19K -317 -3%
UBS Group
13
UBS Group
Switzerland
$57K +$25.9K +3,757 +56%
Royal Bank of Canada
14
Royal Bank of Canada
Ontario, Canada
$57K +$72.9K +10,560 New
Osaic Holdings
15
Osaic Holdings
Arizona
$54K +$69.3K +10,050 New
BCV
16
Banque Cantonale Vaudoise
Switzerland
$16K – – –
TRCT
17
Tower Research Capital (TRC)
New York
$7K +$4.24K +615 +111%
Morgan Stanley
18
Morgan Stanley
New York
$4K – – –
IAP
19
Indie Asset Partners
Indiana
– -$221K -29,652 Closed
SPIA
20
Steward Partners Investment Advisory
New York
– -$1K -100 Closed

GANX Hedge Fund Activity: Q4 2021 in Review

19 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Gain Therapeutics (GANX) for Q4 2021, worth a combined $5.71M — down 14% from $6.65M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new GANX positions and 2 closed out — a net gain of 5 holders — while 4 added to existing stakes and 1 trimmed.

The largest buyer was Telemetry Investments, adding an estimated $379K. The largest seller was Indie Asset Partners, exiting entirely with an estimated $221K sold.

  • 19 institutional investors held Gain Therapeutics (GANX) as of Q4 2021, up from 14 in Q3 2021.
  • Funds reported $5.71M of Gain Therapeutics stock for Q4 2021, down 14% quarter-over-quarter.
  • 7 funds opened new Gain Therapeutics positions in Q4 2021 and 2 closed out, a net change of +5 holders.
  • The largest Gain Therapeutics buyer in Q4 2021 was Telemetry Investments, an estimated $379K added.
  • The largest Gain Therapeutics seller in Q4 2021 was Indie Asset Partners, an estimated $221K sold.

Based on aggregated 13F filings for Q4 2021.